Novel strategies for treating candidiasis

Current Opinion in Infectious Diseases

Volumn 12, Issue 1, 1999, Pages 61-66

  Polonelli, Luciano ^a   Cassone, Antonio ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE;

CANDIDIASIS; HUMAN; IMMUNOTHERAPY; NEPHROTOXICITY; REVIEW; SIDE EFFECT;

EID: 0033041647     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199902000-00011     Document Type: Review

References (41)

1. Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs 1997; 54:657-678.
2. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35.79-86.
3. Rodriguez LJ, Rex JH, Anaissie EJ. Update on invasive candidiasis. Adv Pharmacol 1997; 37.349-400.
4. Romani L, Bistoni F, Puccetti P. Initiation of T-helper cell immunity to Candida albicans by IL-12. the role of neutrophils. Chem Immunol 1997; 68:110-135.
5. Vázquez-Torres A, Balish E. Macrophages in resistance to candidiasis Microbiol Mol Biol Rev 1997; 61:170-192.
6. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238-245.
7. Rex JH, Walsh TJ, Anaissie EJ. Fungal infections in iatrogenically compromised hosts. Adv Intern Med 1998; 43:321-371.
8. Wade JC. Treatment of fungal and other opportunistic infections in immunocompromised patients. Leukemia 1997; 1 (Suppl 4):538-539.
9. Marichal P, Vanden Bossche H, Odds FC, Nobels O, Warnock DW, Timmerman V, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997; 41.2229-2237.
10. Walsh TJ, Kasai M, Francesconi A, Landsman D, Chanock SJ. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes:implications for antifungal azole resistance. J Med Vet Mycol 1997; 35:133-137.
11. Bartroh J, Turmo E, Alguerá M, Boncompte E, Vericat ML, Conte L, et al. New azoles antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azotyl-2-butanol. J Med Chem 1998; 41:1855-1868.
12. Tsuruoka A, Kaku Y, Kakinuma H, Tsukada I, Yanagisawa M, Nara K, Naito T. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives. Chem Pharm Bull (Tokyo) 1998; 46.623-630.
13. Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans. effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42:907-910.
14. Qian Q, Cutler JE. Gamma Interferon is not essential in host defense against disseminated candidiasis in mice. Infect Immun 1997; 65:1748-1753.
15. Ghannoum MA. Susceptibility testing of fungi and correlation with clinical outcome. J Chemother 1997; 9 (Suppl 1):19-24.
16. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifingal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candidal infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24:235-247.
17. Walsh TJ, Whitcomb P, Piscitelli S, Figg WD, Hill S, Chanock SJ, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with epatospeenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944-1948.
18. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy 556 cases Clin Infect Dis 1998; 26.1383-1396. This is a thorough investigation of both the safety and efficacy of a lipid complex of AmB with an emphasis on renal function in difficult-to-treat patients who proved refractory to AmB.
19. Swenson CE, Perkins WR, Roberts P, Ahmad I, Stevens R, Stevens DA, Janoff AS. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998, 42 767-771.
20. Anaissie EJ, Mattiuzzi GN Miller CB, Noskin GA, Gurwith MJ, Mamelok RD, Pietrelli LA. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998; 42:606-611.
21. Romani L, Mencacci A, Cenci E, Del Sero G, Bistoni F, Puccetti P An immunoregulatory role far neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol 1997; 158:2356-2362.
22. Romani L, Mencacci A, Cenci E, Spaccapelo R, Del Sero G, Nicoletti I, et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997, 158:5349-5356. The production of neutrophil as a central machine in anti-Candida response is demonstrated The authors offer solutions and discuss problems.
23. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11:1621-1630.
24. Natarajan U, Randhawa N, Brummer E, Stevens DA. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. J Med Microbiol 1998; 47:359-363.
25. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998; 26:1270-1278.
26. Cohen DM, Bhalla SC, Anaissie EJ, Hester JP, Savary CA, Rex JH. Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy. Clin Lab Haematol 1997; 19:39-47.
27. Kaposzta R, Tree P, Marodi L, Gordon S. Characteristics of invasive candidiasis in gamma Interferon- and interieukin-4-deficient mice, role of macrophages in host defense against Candida albicans. Infect Immun 1998; 66:1708-1717.
28. Bromuro C, La Valle R, Sandini S, Urbani F, Ausiello CM, Morelli L, et al. A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun 1998; 66:2154-2162
29. Mencacci A, Del Sero G, Cenci E, d'Ostiani CF, Bacci A, Montagnoli C, et al. Endogenous interleukin 4 is required for development of protective CD4+ T helper type I cell responses to Candida albicans. J Exp Med 1998; 187:307-317. A scholarly illustration of the complexity of host response to Candida and the tricky nature of some cytokines in the balance of protective versus non protective responses.
30. Kobayashi M, Kobayashi H, Herndon DN, Pollard RB, Suzuki F. Burn-associated Candida albicans infection caused by CD30+ type 2 T cells. J Leukoc Biol 1998, 63:723-731.
31. Roilides E, Kadiltsoglou I, Dimitriadou A, Hatzìstilianou M, Manitsa A, Karpouzas I, et al. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with a decreased uptake of blastoconidia. FEMS Immunol Med Microbiol 1997; 19:169-180.
32. Mack VE, McCarter MD, Naama HA, Calvano SE, Daly IM. Candida infection following severe trauma exacerbates Th2 cytokines and increases mortality. J Surg Res 1997; 69:399-407.
33. Han Y, Cutler JE Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J Infect Dis 1997; 175:1169-1175.
34. Han Y, Kanbe T, Cherniak R, Cutler JE. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 1997; 65:4100-4107. This is one of the first and best demonstrations of how to search for vaccine-relevant antigenic determinants, which also demonstrates the importance of antibody response in systemic candidiasis.
35. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A. Protective role of anti-mannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats Infect Immun 1997; 65:165-197
36. Cassone A, Conti S, De Bernardis F, Polonelli L. Antibodies, killer toxins and antifungal immunoprotection, a lesson from nature? Immunol Today 1997; 18:164-169. A critical perspective of the role of antibodies, in particular those mimicking yeast killer toxins, for anti-candidal immunotherapy.
37. Magliani W, Conti S, De Bernardis F, Gerloni M, Bertolotti D, Mozzoni P, et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity Nature Biotechnol 1997; 15:155-158. The first demonstration of in-vitro and in-vivo anti-candidal activity of single chain fragment variable antibodies mimicking yeast killer toxins.
38. Magliani W, Conti S, Gerloni M, Bertolotti D, Polonelli L. Yeast killer systems Clin Microbiol Rev 1997; 10:369-400.
39. Cenci E, Mencacci A, Del Sera O, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an Interleukin-4 antagonist. J Infect Dis 1997; 176:217-226.
40. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26:1266-1269.
41. Anaissie EJ. Immunomodulation for the treatment of invasive fungal infections. Clin Infect Dis 1998; 26:1264-1265.